Tomichek Jason E, Stollings Joanna L, Pandharipande Pratik P, Chandrasekhar Rameela, Ely E Wesley, Girard Timothy D
Department of Pharmaceutical Services, Vanderbilt University Medical Center, 1211 Medical Center Drive, Nashville, TN, 37232-7610, USA.
Department of Anesthesiology, Division of Critical Care, Vanderbilt University School of Medicine, 1211 21st Ave S, Nashville, TN, 37212, USA.
Crit Care. 2016 Nov 24;20(1):378. doi: 10.1186/s13054-016-1557-1.
Antipsychotics are used to treat delirium in the intensive care unit (ICU) despite unproven efficacy. We hypothesized that atypical antipsychotic treatment in the ICU is a risk factor for antipsychotic prescription at discharge, a practice that might increase risk since long-term use is associated with increased mortality.
After excluding patients on antipsychotics prior to admission, we examined antipsychotic use in a prospective cohort of ICU patients with acute respiratory failure and/or shock. We collected data on medication use from medical records and assessed patients for delirium using the Confusion Assessment Method for the ICU. Using multivariable logistic regression, we analyzed whether age, delirium duration, atypical antipsychotic use, and discharge disposition (each selected a priori) were independent risk factors for discharge on an antipsychotic. We also examined admission Acute Physiology and Chronic Health Evaluation (APACHE) II score, haloperidol use, and days of benzodiazepine use in post hoc analyses.
After excluding 18 patients due to prior antipsychotic use and three who withdrew, we included 500 patients. Among 208 (42%) treated with an antipsychotic, median (interquartile range) age was 59 (49-69) years and APACHE II score was 26 (22-32), characteristics that were similar among antipsychotic nonusers. Antipsychotic users were more likely than nonusers to have had delirium (93% vs. 61%, p < 0.001). Of the 208 antipsychotic users, 172 survived to hospital discharge, and 42 (24%) of these were prescribed an antipsychotic at discharge. Treatment with an atypical antipsychotic was the only independent risk factor for antipsychotic prescription at discharge (odds ratio 17.6, 95% confidence interval 4.9 to 63.3; p < 0.001). Neither age, delirium duration, nor discharge disposition were risk factors (p = 0.11, 0.38, and 0.12, respectively) in the primary regression model, and post hoc analyses found APACHE II (p = 0.07), haloperidol use (p = 0.16), and days of benzodiazepine use (p = 0.31) were also not risk factors for discharge on an antipsychotic.
In this study, antipsychotics were used to treat nearly half of all antipsychotic-naïve ICU patients and were prescribed at discharge to 24% of antipsychotic-treated patients. Treatment with an atypical antipsychotic greatly increased the odds of discharge with an antipsychotic prescription, a practice that should be examined carefully during medication reconciliation since these drugs carry "black box warnings" regarding long-term use.
尽管疗效未经证实,但抗精神病药物仍被用于治疗重症监护病房(ICU)中的谵妄。我们推测,在ICU中使用非典型抗精神病药物是出院时开具抗精神病药物处方的一个风险因素,由于长期使用与死亡率增加相关,这种做法可能会增加风险。
在排除入院前使用抗精神病药物的患者后,我们对一组患有急性呼吸衰竭和/或休克的ICU患者进行了前瞻性队列研究,观察抗精神病药物的使用情况。我们从病历中收集用药数据,并使用ICU谵妄评估方法对患者的谵妄情况进行评估。通过多变量逻辑回归分析,我们分析了年龄、谵妄持续时间、非典型抗精神病药物的使用以及出院处置方式(均为预先选定)是否是出院时开具抗精神病药物处方的独立风险因素。我们还在事后分析中检查了入院时的急性生理与慢性健康状况评估(APACHE)II评分、氟哌啶醇的使用情况以及苯二氮䓬类药物的使用天数。
在排除18例因先前使用抗精神病药物以及3例退出研究的患者后,我们纳入了500例患者。在208例(42%)接受抗精神病药物治疗的患者中,年龄中位数(四分位间距)为59岁(49 - 69岁),APACHE II评分为26分(22 - 32分),这些特征在未使用抗精神病药物的患者中相似。使用抗精神病药物的患者比未使用者更有可能出现谵妄(93%对61%,p < 0.001)。在208例使用抗精神病药物的患者中,172例存活至出院,其中42例(24%)在出院时被开具了抗精神病药物处方。使用非典型抗精神病药物治疗是出院时开具抗精神病药物处方的唯一独立风险因素(比值比17.6,95%置信区间4.9至63.3;p < 0.001)。在主要回归模型中,年龄、谵妄持续时间和出院处置方式均不是风险因素(p分别为0.11、0.38和0.12),事后分析发现APACHE II评分(p = 0.07)、氟哌啶醇的使用(p = 0.16)以及苯二氮䓬类药物的使用天数(p = 0.31)也不是出院时开具抗精神病药物处方的风险因素。
在本研究中,近一半未使用过抗精神病药物的ICU患者接受了抗精神病药物治疗,且24%接受抗精神病药物治疗的患者在出院时被开具了此类药物。使用非典型抗精神病药物治疗显著增加了出院时开具抗精神病药物处方的几率,由于这些药物存在关于长期使用的“黑框警告”,在药物核对过程中应仔细审查这种做法。